Dr Thomas Rasmussen is a Clinical Research Fellow in Professor Sharon Lewin’s laboratory. Thomas has a Doctor of Medicine degree from Aarhus University, Denmark in 2006 and has since been involved in clinical infectious disease medicine and HIV-related science with research activities primarily including clinical, translational and epidemiological studies. He completed his PhD in HIV in 2014, which was focused on the clinical use of histone deacetylase inhibitors to reverse HIV-1 latency. Thomas’ ongoing research is focused at understanding the barriers to curing HIV-1 infection and testing new strategies aimed at eliminating latent HIV-1 infection.
Based at Aarhus University Hospital, Denmark, Thomas has led a pre-clinical study of histone deacetylase inhibitors and their potential use in HIV-1 infection. Subsequently, he was the principal investigator on a phase I/IIa clinical trial investigating the effect of the histone deacetylase inhibitor, panobinostat, on HIV-1 latency in patients with chronic HIV-1 infection. The primary results of this study, which was funded by a grant from The Danish Research Council, were published in The Lancet HIV in October, 2014. He is also an investigator on several on-going clinical studies investigating interventions aimed at the development of a cure for HIV.
Full University of Melbourne profile